Evidence map›Paper›PMID 40231553›Full record

ArticleCancer medicine2025

Performance of a Logistic Regression Model Using Paired miRNAs to Stratify Abnormal Mammograms for Benign Breast Lesions.

Hideo Akiyama, Lora Barke, Therese B Bevers, Suzanne J Rose, Jennifer J Hu, Kelly A McAleese, Shellie S Campos, Satoshi Kondou, Jun Atsumi, Thomas F Soriano

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hideo AkiyamaToray Industries, Inc., Kamakura, Kanagawa, Japan.ORCID https://orcid.org/0009-0001-1555-7253
Lora BarkeInvision Sally Jobe/Radiology Imaging Associates, Englewood, Colorado, USA.
Therese B BeversDivision of OVP, Department of Clinical Cancer Prevention, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Suzanne J RoseDepartment of Research and Discovery, Stamford Health, Breast Center, Stamford Health, Stamford, Connecticut, USA.ORCID https://orcid.org/0000-0001-5770-826X
Jennifer J HuDepartment of Public Health Science, University of Miami School of Medicine, Miami, Florida, USA.
Kelly A McAleeseThe Women's Imaging Center, Denver, Colorado, USA.
Shellie S CamposJohn Muir Health, Walnut Creek and Concord, California, USA.
Satoshi KondouToray Industries, Inc., Kamakura, Kanagawa, Japan.
Jun AtsumiToray Industries, Inc., Tokyo, Japan.
Thomas F SorianoDiagnostic Oncology CRO, LLC, Oxford, Connecticut, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMammography is effective in reducing breast cancer mortality, but it has false positive results that cause subsequent interventions such as biopsy or interval repeat mammography. Thus, there is a clinical unmet need for accurate molecular classifiers that can reduce unnecessary additional imaging and/or invasive diagnostic procedures for low-risk women.

methodWe performed miRNA profiling on a prospectively collected serum specimen obtained from each of the 432 subjects who received an abnormal mammogram or imaging result and then selected 265 subjects for further analysis. The miRNA classifier, named EarlyGuard, was generated based on a novel logistic regression model using "paired miRNAs" where the two miRNAs of interest exhibit the same properties.

resultsThe classifier developed using the training set of 174 subjects enrolled at seven investigative sites resulted in a negative predictive value (NPV) and a sensitivity of 96.4% and 91.2%, respectively. The classifier was validated using the test set consisting of 91 subjects enrolled at three investigative sites, two of which were not included in the training set. The resulting NPV and sensitivity were estimated similarly to be 96.9% and 95.8%, respectively.

conclusionsOur miRNA classifier has produced promising results that could be used in conjunction with mammography or other imaging procedures to reduce unnecessary invasive diagnostic procedures for women who are unlikely to have a suspicious or worse result on a subsequent diagnostic biopsy. Additional studies will be conducted in larger cohorts to determine if the sensitivity of the classifier will be improved.

Indexed as

Breast NeoplasmsMammographyMicroRNAsAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansLogistic ModelsMiddle AgedBiomarkers, TumorMicroRNAsabnormal mammogrambenign breast lesionsbreast cancerliquid biopsyserum miRNA

Identifiers

PMID40231553
PMCPMC11997706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.